{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"MTD was highest dose of Ixazomib, at which \\<=1 of 6 participants experienced dose-limiting toxicity (DLT) during Cycle 1 of Phase 1. DLT was defined as any of following considered possibly related to therapy: Grade 4 neutropenia (absolute neutrophil count \\[ANC\\] \\<500 cell per cubic millimeter \\[cells/mm\\^3\\]) for \\>7 days;Grade 3 neutropenia with fever or infection; Grade 4 thrombocytopenia (platelets \\< 25,000/mm\\^3) for \\>7 days;Grade 3 thrombocytopenia with clinically significant bleeding; platelet count \\<10,000/mm\\^3; Grade 2 peripheral neuropathy with pain or \\>=Grade 3 peripheral neuropathy; \\>=Grade 3 nausea/emesis, diarrhea controlled by supportive therapy; Grade 3 QTc prolongation (QTc \\>500 millisecond \\[msec\\]);any \\>=Grade 3 nonhematologic toxicity except Grade 3 arthralgia/myalgia; or \\<1 week Grade 3 fatigue; delay in initiation of the subsequent therapy cycle by \\>2 weeks; other \\>=Grade 2 study drug-related nonhematologic toxicities requiring therapy discontinuation.","groups":[{"description":"All participants who received ixazomib 0.24 mg/m\\^2, 0.48 mg/m\\^2, 0.8 mg/m\\^2, 1.2 mg/m\\^2, 1.68 mg/m\\^2, 2 mg/m\\^2 or 2.23 mg/m\\^2 in dose-escalation cohorts.","id":"OG000","title":"Ixazomib (All Groups)"}],"paramType":"NUMBER","populationDescription":"DLT-evaluable population was defined as all participants who received all Cycle 1 doses of ixazomib and completed Cycle 1 or who experienced DLT in Cycle 1.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (21 days)","title":"Maximum Tolerated Dose (MTD) of Ixazomib","type":"PRIMARY","unitOfMeasure":"mg/m^2"}